Pharmacogenomic strategies provide a rational approach to the treatment of cisplatin-resistant patients with advanced cancer (Q34695697)

Dataset for "Continued use of retracted papers: Temporal trends in citations and (lack of) awareness of retractions shown in citation contexts in biomedicine"

4 August 2017

2 references

Continued use of retracted papers: Temporal trends in citations and (lack of) awareness of retractions shown in citation contexts in biomedicine

title

Pharmacogenomic strategies provide a rational approach to the treatment of cisplatin-resistant patients with advanced cancer (English)

1 reference

4 August 2017

0 references

1 reference

David S Hsu

1

1 reference

4 August 2017

Bala S Balakumaran

2

1 reference

4 August 2017

Chaitanya R Acharya

3

1 reference

4 August 2017

Vanja Vlahovic

4

1 reference

4 August 2017

Kelli S Walters

5

1 reference

4 August 2017

Katherine Garman

6

1 reference

4 August 2017

Carey Anders

7

1 reference

4 August 2017

Richard F Riedel

8

1 reference

4 August 2017

Johnathan Lancaster

9

1 reference

4 August 2017

David Harpole

10

1 reference

4 August 2017

Holly K Dressman

11

1 reference

4 August 2017

Joseph R Nevins

12

1 reference

4 August 2017

Phillip G Febbo

13

1 reference

4 August 2017

Anil Potti

14

1 reference

4 August 2017

language of work or name

English

0 references

publication date

1 October 2007

1 reference

Journal of Clinical Oncology

4 August 2017

1 reference

4 August 2017

25

1 reference

4 August 2017

28

1 reference

4 August 2017

4350-4357

1 reference

Genomic signatures to guide the use of chemotherapeutics.

4 August 2017

1 reference

30 December 2023

https://opencitations.net/index/api/v1/citations/10.1038/NM1491

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://opencitations.net/index/api/v1/references/10.1200/JCO.2007.11.0593

Genome-wide views of cancer

9 February 2024

1 reference

https://opencitations.net/index/api/v1/references/10.1200/JCO.2007.11.0593

Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer

9 February 2024

1 reference

https://opencitations.net/index/api/v1/references/10.1200/JCO.2007.11.0593

A molecular signature of metastasis in primary solid tumors

9 February 2024

1 reference

https://opencitations.net/index/api/v1/references/10.1200/JCO.2007.11.0593

Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non--small-cell lung cancer: a Southwest Oncology Group trial

9 February 2024

1 reference

https://opencitations.net/index/api/v1/references/10.1200/JCO.2007.11.0593

Comparison of CA-125 and standard definitions of progression of ovarian cancer in the intergroup trial of cisplatin and paclitaxel versus cisplatin and cyclophosphamide

9 February 2024

1 reference

https://opencitations.net/index/api/v1/references/10.1200/JCO.2007.11.0593

Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays

9 February 2024

1 reference

https://opencitations.net/index/api/v1/references/10.1200/JCO.2007.11.0593

Twenty-two years of phase III trials for patients with advanced non-small-cell lung cancer: sobering results

9 February 2024

1 reference

https://opencitations.net/index/api/v1/references/10.1200/JCO.2007.11.0593

A gene-expression signature as a predictor of survival in breast cancer

9 February 2024

1 reference

https://opencitations.net/index/api/v1/references/10.1200/JCO.2007.11.0593

Molecular classification of cancer: class discovery and class prediction by gene expression monitoring

9 February 2024

1 reference

https://opencitations.net/index/api/v1/references/10.1200/JCO.2007.11.0593

Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning

9 February 2024

1 reference

https://opencitations.net/index/api/v1/references/10.1200/JCO.2007.11.0593

Enhanced host cell reactivation capacity and expression of DNA repair genes in human breast cancer cells resistant to bi-functional alkylating agents

9 February 2024

1 reference

https://opencitations.net/index/api/v1/references/10.1200/JCO.2007.11.0593

Oncogenic pathway signatures in human cancers as a guide to targeted therapies

9 February 2024

1 reference

https://opencitations.net/index/api/v1/references/10.1200/JCO.2007.11.0593

Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group.

9 February 2024

1 reference

https://opencitations.net/index/api/v1/references/10.1200/JCO.2007.11.0593

Erlotinib in previously treated non-small-cell lung cancer

9 February 2024

1 reference

https://opencitations.net/index/api/v1/references/10.1200/JCO.2007.11.0593

Bayesian analysis of binary prediction tree models for retrospectively sampled outcomes.

9 February 2024

1 reference

https://opencitations.net/index/api/v1/references/10.1200/JCO.2007.11.0593

Review of a promising new agent--pemetrexed disodium

9 February 2024

1 reference

https://opencitations.net/index/api/v1/references/10.1200/JCO.2007.11.0593

Role of platinum-DNA adduct formation and removal in cisplatin resistance in human ovarian cancer cell lines

9 February 2024

1 reference

https://opencitations.net/index/api/v1/references/10.1200/JCO.2007.11.0593

The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma

9 February 2024

1 reference

https://opencitations.net/index/api/v1/references/10.1200/JCO.2007.11.0593

Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy

9 February 2024

1 reference

https://opencitations.net/index/api/v1/references/10.1200/JCO.2007.11.0593

Characterization of the cellular reduction of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT): subcellular localization, substrate dependence, and involvement of mitochondrial electron transport in MTT reduction

9 February 2024

1 reference

https://opencitations.net/index/api/v1/references/10.1200/JCO.2007.11.0593

Gene expression profiling of 30 cancer cell lines predicts resistance towards 11 anticancer drugs at clinically achieved concentrations.

9 February 2024

1 reference

https://opencitations.net/index/api/v1/references/10.1200/JCO.2007.11.0593

A genomic strategy to refine prognosis in early-stage non-small-cell lung cancer.

9 February 2024

2 references

https://opencitations.net/index/api/v1/references/10.1200/JCO.2007.11.0593

9 February 2024

9 February 2024

https://opencitations.net/index/api/v1/citations/10.1056/NEJMOA060467

Molecular portraits of human breast tumours

1 reference

https://opencitations.net/index/api/v1/references/10.1200/JCO.2007.11.0593

9 February 2024

Identifiers

DOI

10.1200/JCO.2007.11.0593

1 reference

4 August 2017

1 reference